Arsenic Exposure and Prevalence of the Varicella Zoster Virus in the United States: NHANES (2003-2004 and 2009-2010) Public Deposited

http://ir.library.oregonstate.edu/concern/articles/fx719p367

This is the publisher’s final pdf. The published article is copyrighted by National Institute of Environmental Health Sciences and reproduced with permission from Environmental Health Perspectives. The published article can be found at:  http://ehp.niehs.nih.gov/

Descriptions

Attribute NameValues
Creator
Abstract or Summary
  • Background: Arsenic is an immunotoxicant. Clinical reports observe the reactivation of varicella zoster virus (VZV) in people who have recovered from arsenic poisoning and in patients with acute promyelocytic leukemia that have been treated with arsenic trioxide. Objective: We evaluated the association between arsenic and the seroprevalence of VZV IgG antibody in a representative sample of the U.S. population. Methods: We analyzed data from 3,348 participants of the National Health and Nutrition Examination Survey (NHANES) 2003–2004 and 2009–2010 pooled survey cycles. Participants were eligible if they were 6–49 years of age with information on both VZV IgG and urinary arsenic concentrations. We used two measures of total urinary arsenic (TUA): TUA1 was defined as the sum of arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid, and TUA2 was defined as total urinary arsenic minus arsenobetaine and arsenocholine. Results: The overall weighted seronegative prevalence of VZV was 2.2% for the pooled NHANES sample. The geometric means of TUA1 and TUA2 were 6.57 μg/L and 5.64 μg/L, respectively. After adjusting for age, sex, race, income, creatinine, and survey cycle, odds ratios for a negative VZV IgG result in association with 1-unit increases in natural log-transformed (ln)-TUA1 and ln-TUA2 were 1.87 (95% CI: 1.03, 3.44) and 1.40 (95% CI: 1.0, 1.97), respectively. Conclusions: In this cross-sectional analysis, urinary arsenic was inversely associated with VZV IgG seroprevalence in the U.S. population. This finding is in accordance with clinical observations of zoster virus reactivation from high doses of arsenic. Additional studies are needed to confirm the association and evaluate causal mechanisms.
Resource Type
DOI
Date Available
Date Issued
Citation
  • Cardenas, A., Smit, E., Houseman, E. A., Kerkvliet, N. I., Bethel, J. W., & Kile, M. L. (2015). Arsenic Exposure and Prevalence of the Varicella Zoster Virus in the United States: NHANES (2003-2004 and 2009-2010). Environmental Health Perspectives, 123(6), 590-596. doi:10.1289/ehp.1408731
Series
Rights Statement
Funding Statement (additional comments about funding)
Publisher
Peer Reviewed
Language
Replaces
Additional Information
  • description.provenance : Approved for entry into archive by Patricia Black(patricia.black@oregonstate.edu) on 2015-08-27T15:21:20Z (GMT) No. of bitstreams: 2 license_rdf: 1089 bytes, checksum: 0a703d871bf062c5fdc7850b1496693b (MD5) CardenasAndresPublicHealthHumanSciArsenicExposurePrevalence.pdf: 489285 bytes, checksum: 5dfc4a0746306e148f7fb93d16303402 (MD5)
  • description.provenance : Submitted by Patricia Black (patricia.black@oregonstate.edu) on 2015-08-27T15:20:31Z No. of bitstreams: 2 license_rdf: 1089 bytes, checksum: 0a703d871bf062c5fdc7850b1496693b (MD5) CardenasAndresPublicHealthHumanSciArsenicExposurePrevalence.pdf: 489285 bytes, checksum: 5dfc4a0746306e148f7fb93d16303402 (MD5)
  • description.provenance : Made available in DSpace on 2015-08-27T15:21:20Z (GMT). No. of bitstreams: 2 license_rdf: 1089 bytes, checksum: 0a703d871bf062c5fdc7850b1496693b (MD5) CardenasAndresPublicHealthHumanSciArsenicExposurePrevalence.pdf: 489285 bytes, checksum: 5dfc4a0746306e148f7fb93d16303402 (MD5) Previous issue date: 2015-06

Relationships

Parents:

This work has no parents.

Last modified

Downloadable Content

Download PDF

Items